4507:TYO
Shionogi & Co Ltd
2Â 744,50Â JPÂ¥
arrow_downward
-0,88%(-24,50) 1D
9 tet, 3:30:00 m.d., GMT+9 · JPY
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për 4507...
Hap
2Â 758Â JPÂ¥
I lartë
2Â 778Â JPÂ¥
I ulët
2Â 734Â JPÂ¥
Kapitalizimi i tregut
2,44Â bln
Vëllimi mesatar
2,93Â mln
Vëllimi
3,31Â mln
Dividendi
2,59%
Dividendi tremujor
18Â JPÂ¥
Data e ndërprerjes së dividendit
29 sht 2026
Raporti çmim/fitim
8,86
Maksimumi 52-javor
3Â 758Â JPÂ¥
Minimumi 52-javor
2Â 392Â JPÂ¥
Fitimet për aksion
310Â JPÂ¥
Aksionet në qarkullim
314,50Â mln
Numri i punonjësve
6 mijë
Hap
2Â 758Â JPÂ¥
I lartë
2Â 778Â JPÂ¥
I ulët
2Â 734Â JPÂ¥
Kapitalizimi i tregut
2,44Â bln
Vëllimi mesatar
2,93Â mln
Vëllimi
3,31Â mln
Dividendi
2,59%
Dividendi tremujor
18Â JPÂ¥
Data e ndërprerjes së dividendit
29 sht 2026
Raporti çmim/fitim
8,86
Maksimumi 52-javor
3Â 758Â JPÂ¥
Minimumi 52-javor
2Â 392Â JPÂ¥
Fitimet për aksion
310Â JPÂ¥
Aksionet në qarkullim
314,50Â mln
Numri i punonjësve
6 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Bloomberg.com
·
1 orë më parë
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
FXLeaders
·
1 orë më parë
Dow Jones and Nasdaq Futures Start Higher Ahead of US Inflation Data
BeInCrypto
·
54 minuta më parë
XRP’s Nasdaq Moment Nears: 5 Things to Know About Evernorth
Yahoo Finance
·
5 orë më parë
Beyond S&P 500 Index Funds: Here's the 1 Sector I'd Buy First as a New Investor
Profili
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Rreth Shionogi & Co Ltd
Drejtori ekzekutivIsao Teshirogi
Punonjësit6,22 mijë
Themeluar më1878
Selia-
Sektori-
Uebsajtishionogi.com